Bortezomib (PS-341)

製品コードS1013 別名:LDP-341, MLM341

Bortezomib (PS-341)化学構造

分子量(MW):384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

サイズ 価格(税別)  
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(148)

カスタマーフィードバック(25)

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  • HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
ターゲット
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 Mm\VR5l1d3SxeHnjJGF{e2G7 MWe1NEDPxE1? MX60PEBp M4HGNmROW09? Ml;2T4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> MVGxNFQ6QTZ2Mx?=
OVCA 429 NYn3WIFQTnWwY4Tpc44hSXO|YYm= NXH0V3IzOzByIH7N M17vZ|Q5KGh? NXjuUVhCTE2VTx?= MXXEbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= MWexNFk6QTd4Nh?=
RPMI8226 M{W2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7ENVAxKG6P MlLzOFghcA>? M1uzeWROW09? MYjJR|UxRTNyIH7N NGK3WZAyOTNyNkS4PS=>
Dox40 NUPDS24zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqzNVAxKG6P Mn65OFghcA>? NILy[WVFVVOR NHnmbGVKSzVyPUSwJI5O NUDOUIlrOTF|ME[0PFk>
MR20 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUixNFAhdk1? MWS0PEBp M2nVNWROW09? MYjJR|UxRTJyIH7N NIHPU4UyOTNyNkS4PS=>
LR5 M3nuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLjZ40yODBibl2= M1rvRVQ5KGh? NV\Jd4pxTE2VTx?= NF[4T3BKSzVyPUKwJI5O MXuxNVMxPjR6OR?=
U266 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nHNFExOCCwTR?= MkXoOFghcA>? M4SwWmROW09? NEDGUVVKSzVyPUOgcm0> MYWxNVMxPjR6OR?=
IM-9 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPQNVAxKG6P NED1Wmk1QCCq MlzwSG1UVw>? M2qyZmlEPTB;NjDuUS=> NUnXWlQ3OTF|ME[0PFk>
Hs Sultan M3XySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;hbVExOCCwTR?= MYq0PEBp M2HpV2ROW09? MXzJR|UxRTJyIH7N M1PTN|EyOzB4NEi5
PAM-LY2 M4jLN2Z2dmO2aX;uJGF{e2G7 NWDWcJpEOTByIH7N M2fUW|EzKGh? NHrPRVJFVVOR NYjZfVBbUW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44> MlPkNVE{PTB7MUO=
PAM 212 NWHCS2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO4N2l5OTByIH7N NX76U3BmPzJiaB?= NV[5WI41TE2VTx?= M4rpWmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NVS0[45ROTF|NUC5NVM>
PAM-LY2 M3n5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorINVAxKG6P NVPuem83PzJiaB?= Mmr2SG1UVw>? NFrhfohKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MXuxNVM2ODlzMx?=
B4B8 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6xNFAhdk1? NWTMVoU1PzJiaB?= NF3XfGpFVVOR MkXITY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MWKxNVM2ODlzMx?=
B7E3 M4XHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxNFAhdk1? MXy3NkBp MoXkSG1UVw>? MXXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NY[xR|FWOTF|NUC5NVM>
UM-SCC-9 NVrudmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnoXVUxOTByIH7N MnK1O|IhcA>? M3WycmROW09? MUnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M1XkcFEyOzVyOUGz
UM-SCC-11B M4fFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixNFAhdk1? MYi3NkBp NYj5bVJ4TE2VTx?= NYDsXWRyUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MXuxNVM2ODlzMx?=
H460 MX3GeY5kfGmxbjDBd5NigQ>? MWmxNEDPxE1? MY[yOEBp M4HlZWROW09? M1T5bmlv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R? M4LS[FEzPDl{MUG3
U266 M1TGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLubmxpPTByIH7nM41t NEL6c|E1QCCq MkHISG1UVw>? MUDJcohq[mm2czDj[YxtKGe{b4f0bC=> NF;aeocyOjZ|MU[xPS=>
ARH77 NEOwNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yzdlUxOCCwZz;tcC=> Ml\vOFghcA>? MYfEUXNQ M1PHT2lvcGmkaYTzJINmdGxiZ4Lve5Rp M4rUPVEzPjNzNkG5
WAD-1 NE\pWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P4Z|UxOCCwZz;tcC=> MVO0PEBp MXzEUXNQ MlXWTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NFPpOYUyOjZ|MU[xPS=>
U266/LR7 NHLseHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO1NFAhdmdxbXy= MYi0PEBp M3m3VmROW09? M4nTbWlvcGmkaYTzJINmdGxiZ4Lve5Rp NWjD[45tOTJ4M{G2NVk>
U266/dox4 Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG4SHFlPTByIH7nM41t NV;HXY84PDhiaB?= M1WxT2ROW09? NIiybWhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NXjQcoRROTJ4M{G2NVk>
RPMI8226/LR5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFyxOoE2ODBibnevcYw> MojGOFghcA>? MVfEUXNQ NWnkT4JWUW6qaXLpeJMh[2WubDDndo94fGh? M3u3[VEzPjNzNkG5
H460 M4HVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNEDPxE1? M13Ec|czKGh? MYPEUXNQ M13sVmlEPTB;MUCwJI5O M3:1e|EzPjNzNkKw
H358 NUHHOIlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNEDPxE1? NX7XVYxrPzJiaB?= NYXlcJVNTE2VTx?= M3S0RWlEPTB;N{Cgcm0> NH7UfHMyOjZ|MU[yNC=>
H322 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny5NVAh|ryP MlvhO|IhcA>? M2D6dWROW09? MkXVTWM2OD14MkCgcm0> NYm3PYQxOTJ4M{G2NlA>
H460 M33u[GZ2dmO2aX;uJGF{e2G7 NXjlV2hoOTByIH7N M{nEfVI1KGh? MUPEUXNQ NVH6SXZHUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?= M4T1UlEzPjNzNkKw
LNCap-Pro5 NGLxUmpHfW6ldHnvckBCe3OjeR?= MVyxJO69VQ>? NH;2W|g1KGh? MVTEUXNQ NHHERVVUfGGkaXzpfoV{KHB3Mx?= M{jKZVE1PjF{NUOy
T29 M1zhcWFxd3C2b4Ppd{BCe3OjeR?= NHX6OG42OCCwTR?= NGDwbng1QCCqIB?= Mln5SG1UVw>? M37nNmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVKxOlc4QDF5OR?=
T29Kt1 M2j4bWFxd3C2b4Ppd{BCe3OjeR?= MnXDOVAhdk1? M1XPXlQ5KGhi NFP4WZdFVVOR M3LPTWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Ml;BNVY4PzhzN{m=
HCT116 MnLTRZBweHSxc3nzJGF{e2G7 NVj0XI9sPTBibl2= NUjrdJVpPDhiaDC= NVjTWHRUTE2VTx?= Mn\hTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MkW0NVY4PzhzN{m=
HKe-3 MUXBdI9xfG:|aYOgRZN{[Xl? M3nTXFUxKG6P NXL5foEyPDhiaDC= NG\vdnhFVVOR Mly0TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MoezNVY4PzhzN{m=
NB-1691 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSxJO69VQ>? M{PJN|czKGh? MYLJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? MmrvNVc3QDl4OES=
CHLA-255 M17FSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWxb4I2OSEQvF2= M2qxblczKGh? NHjLNFVKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= M1TjcVE4Pjh7Nki0
SK-N-AS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\FNUDPxE1? MYe3NkBp MojJTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= NHm1NooyPzZ6OU[4OC=>
NB-1691 M3Hkc2Z2dmO2aX;uJGF{e2G7 M2DsdFExKG6P NULFPY9KOjRiaB?= NYXKR|cxW2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? MUixO|Y5QTZ6NB?=
CHLA-255 MV\GeY5kfGmxbjDBd5NigQ>? MYWxNEBvVQ>? NI\hRmgzPCCq NV3hPWNZVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W= MYWxO|Y5QTZ6NB?=
RPMI 8226 M2jlSWZ2dmO2aX;uJGF{e2G7 NIPYZZozOCCwTR?= M2jUPFghcA>? Ml\QV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MV6xPVQ{PjB3MB?=
MM.1S M2XJUGZ2dmO2aX;uJGF{e2G7 MVqyNEBvVQ>? MmPSPEBp M3LobHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MnXWNVk1OzZyNUC=
U266 NHfveWNHfW6ldHnvckBCe3OjeR?= MnrCNlAhdk1? NFTzOYY5KGh? MYrTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M4LCclE6PDN4MEWw
OPM1 MWDGeY5kfGmxbjDBd5NigQ>? MmHvNlAhdk1? MlXZPEBp NXKyXoFtW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MkSwNVk1OzZyNUC=
INA6 NUHnWGZ[TnWwY4Tpc44hSXO|YYm= MV:yNEBvVQ>? MlftPEBp M1GydnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MYexPVQ{PjB3MB?=
OPM2 NGPyflVHfW6ldHnvckBCe3OjeR?= MV6yNEBvVQ>? MkLGPEBp NVS3ZnVJW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NUfMe2tOOTl2M{[wOVA>
RPMI 8226 M1\wUmZ2dmO2aX;uJGF{e2G7 NELE[ZUzOCCwTR?= NGTrb3Q5KGh? M3:2Zmlv\HWlZYOgSG5CKHO7boTo[ZNqew>? NYDxWo5zOTl2M{[wOVA>
BaF/3 NIfobnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDzdo8yODBibl2= NEX3XZE1QCCq MnT0TWM2OD14LkKgcm0> M2fDcVIxOzB3Nkmy
BaF/3-p210 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nVZ|ExOCCwTR?= M{fzUVQ5KGh? MWfJR|UxRTRwNzDuUS=> NHnuRW4zODNyNU[5Ni=>
TCC-S NELGNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[5UVExOCCwTR?= M17LUVQ5KGh? M{L2bWlEPTB;Mj64JI5O NX7ST2NPOjB|MEW2PVI>
BaF/3 NWXWTmRQTnWwY4Tpc44hSXO|YYm= MoPzOkBvVQ>? MmrFOFghcA>? MUnJcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S= NHH2dXYzODNyNU[5Ni=>
BaF/3-p210 MVLGeY5kfGmxbjDBd5NigQ>? MljhOkBvVQ>? M2jLV|Q5KGh? Ml;ETY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> MkHMNlA{ODV4OUK=
BaF/3-p210 MULGeY5kfGmxbjDBd5NigQ>? MXe2JI5O M37QSVI1KGh? NFHndotT\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?= NH\vO|IzODNyNU[5Ni=>
Raji NYLDN5ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXlNUDPxE1? MkiyNlQhcA>? MmPaVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M1XnSFIyOTdyOUi4
LCL-1 NV\5SlBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjT[FYyKM7:TR?= NYXiUFNDOjRiaB?= Mki3VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MlrNNlEyPzB7OEi=
LCL-2 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHUe2xjOSEQvF2= MorFNlQhcA>? NYfGblM3WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MViyNVE4ODl6OB?=
BJAB MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\R[|Eh|ryP MlLSNlQhcA>? NWq5V3poWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NV\IRod4OjFzN{C5PFg>
SNT-13 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\oOIMyKM7:TR?= MlLmNlQhcA>? MXXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MnntNlEyPzB7OEi=
SNT-16 NGrsdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfONUDPxE1? MkTvNlQhcA>? M13Q[nJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M1HXW|IyOTdyOUi4
Jurkat MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G2cFEh|ryP NILpUoszPCCq NITrNXZT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NF3zUlgzOTF5MEm4PC=>
KAI-3 NYTIRWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:4VIkyKM7:TR?= MkHtNlQhcA>? NWLhfnVjWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NH7yd2IzOTF5MEm4PC=>
SNK-6 NGjtXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnaeGkyKM7:TR?= MVuyOEBp M{jtcnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NIT2[YgzOTF5MEm4PC=>
KHYG-1 NFe2NHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXWOZVROSEQvF2= MUWyOEBp NUnyTmNSWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg Mn\BNlEyPzB7OEi=
SNT-16 NWqwN2xnSXCxcITvd4l{KEG|c3H5 NWDmfWw1OSEQvF2= NF3yc483KGh? NYiyVHllUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NEXqeHozOTF5MEm4PC=>
Jurkat NEm4VpdCeG:ydH;zbZMhSXO|YYm= M161eVEh|ryP NUKzd5JCPiCq MmCzTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVuyNVE4ODl6OB?=
KAI-3 M3ziUmFxd3C2b4Ppd{BCe3OjeR?= MX[xJO69VQ>? M3iyb|YhcA>? Mln6TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MmK5NlEyPzB7OEi=
KHYG-1 NF3xTZBCeG:ydH;zbZMhSXO|YYm= M{e5eFEh|ryP NHPNW3k3KGh? M1;qXGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXnqO3MxOjFzN{C5PFg>
SNT-13 M3HEPWFvfGm4aYLhcEBCe3OjeR?= MYmxJO69VQ>? MWeyOEBp MknNTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MVmyNVE4ODl6OB?=
SNT-16 M4O4e2FvfGm4aYLhcEBCe3OjeR?= MUCxJO69VQ>? M1XiZVI1KGh? MorCTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MXGyNVE4ODl6OB?=
KAI-3 NUDkeZBoSW62aY\pdoFtKEG|c3H5 NHTMVpoyKM7:TR?= M1XD[VI1KGh? NV22cGxmUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M1PncVIyOTdyOUi4
SNK-6 Mlf6RY51cX[rcnHsJGF{e2G7 NEP0fHYyKM7:TR?= NEPEeIwzPCCq NUDuR4xqUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY NI\ucHAzOTF5MEm4PC=>
RAW 264.7 M2HzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorBNVAxKG6P Mo\UOFghcA>? M1\LSHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MXuyNlQzPzF3NB?=
A375 NGfkW4xCeG:ydH;zbZMhSXO|YYm= NHXROocyOCCwTR?= M2PaU|I1KGh? NUe5VVdIUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M2m3bFI{ODd7MEiz
BLM MXrBdI9xfG:|aYOgRZN{[Xl? NEDvOlAyOCCwTR?= NY\hbXJ7OjRiaB?= M1;XZ2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUeyN|A4QTB6Mx?=
A375 MnvyRZV1d3CqYXf5JGF{e2G7 M2fLXVExKG6P NGrUVVcyOiCq MlzMTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= MkjwNlMxPzlyOEO=
BLM MlHzRZV1d3CqYXf5JGF{e2G7 MV[xNEBvVQ>? MofDNVIhcA>? MlrVTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NYP4d2lsOjNyN{mwPFM>
H1299 MnLmRZBweHSxc3nzJGF{e2G7 MVi4NEBvVQ>? MVGyOEBp MULEUXNQ MXfT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? MmDkNlU{OjN4OUO=
Hut-78 Mn;HSpVv[3Srb36gRZN{[Xl? MmH1NVAxKG6P MljGNlQhcA>? MojhSG1UVw>? MlfNSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w MUSyOVY5OTN|NR?=
H9 M2\NOWZ2dmO2aX;uJGF{e2G7 MYWxNFAhdk1? NFzCZmkzPCCq NILPUndFVVOR M2PuR2Rwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= M1PHWFI2PjhzM{O1
HH MoLSSpVv[3Srb36gRZN{[Xl? MoLnNVAxKG6P M4[5[|I1KGh? MVzEUXNQ MXzkc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? M1HpXlI2PjhzM{O1
Hut-78 M3\Fb21q\3KjdHnvckBCe3OjeR?= M3fVclExOCCwTR?= MlvWNlQhcA>? M1XEZmROW09? NFizTlBT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl MoDPNlU3QDF|M{W=
HH M3nHdW1q\3KjdHnvckBCe3OjeR?= Ml3PNVAxKG6P MXeyOEBp M1rGOmROW09? M2G3OXJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= MVqyOVY5OTN|NR?=
U937 NV3oeI5nTnWwY4Tpc44hSXO|YYm= M2GwNFExOCCwTR?= M33IblYhcA>? M1LRWGlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? Ml\yNlU4QTF2N{e=
human PBMC M4PnTWZ2dmO2aX;uJGF{e2G7 MWCxNFAhdk1? NHfoXVAzPCCq Mn;ETY5lfWOnczDJUE05KHKnbHXhd4U> NVPM[FhUOjV5OUG0O|c>
ES6 NUHwemppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H3TGlEPTB;MD6wNFIyKG6P MUPTRW5ITVJ?
SK-UT-1 NILHW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMU[zJI5O M4XtNXNCVkeHUh?=
SH-4 M4jzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMUezJI5O NYnHbIdPW0GQR1XS
TE-9 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yyV2lEPTB;MD6xPFIhdk1? NFK4[mNUSU6JRWK=
A253 NFK0XmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;TR2tKSzVyPUCuNlA5KG6P Mo\aV2FPT0WU
no-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnNdWgyUUN3ME2wMlIyKG6P NF3a[G5USU6JRWK=
MMAC-SF MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjnb2dkUUN3ME2wMlIyPiCwTR?= Mmq1V2FPT0WU
A101D NHK1ZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\vZlZtUUN3ME2wMlIzPSCwTR?= NWC4dJBFW0GQR1XS
NTERA-S-cl-D1 NGDrW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfpTWM2OD1yLkK0N{BvVQ>? MmfRV2FPT0WU
8-MG-BA MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMkWgcm0> M4\IUnNCVkeHUh?=
KNS-42 NIXMbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMkW4JI5O Mm\uV2FPT0WU
LXF-289 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzsTWM2OD1yLkK2PUBvVQ>? MY\TRW5ITVJ?
OVCAR-4 M3PIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMki5JI5O NGfNSIdUSU6JRWK=
LOUCY MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDDNmdKSzVyPUCuNlk{KG6P MoX4V2FPT0WU
BB65-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PubmlEPTB;MD6zNFQhdk1? MmfxV2FPT0WU
D-542MG M2P4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwM{K5JI5O NXrMUJN4W0GQR1XS
ONS-76 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vwN2lEPTB;MD6zN{BvVQ>? M3HqU3NCVkeHUh?=
BB30-HNC NVnG[ml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKyOXdzUUN3ME2wMlM{PSCwTR?= NHHnWmZUSU6JRWK=
KS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTabWMyUUN3ME2wMlM1KG6P MVjTRW5ITVJ?
A388 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjzNGlSUUN3ME2wMlM2PiCwTR?= MVXTRW5ITVJ?
ES8 NXLuSoN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPESm1wUUN3ME2wMlQhdk1? NVv4elI{W0GQR1XS
MZ2-MEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDheG9KSzVyPUCuOFA4KG6P NVHvOIxzW0GQR1XS
HCC2998 NWf2bIg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLFTWM2OD1yLkSxNkBvVQ>? MXfTRW5ITVJ?
D-247MG M3X2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfSVpNKSzVyPUCuOFE{KG6P M2fjOHNCVkeHUh?=
ACN MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX3R25xUUN3ME2wMlQyPyCwTR?= M1;oZnNCVkeHUh?=
LB2518-MEL MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OxTGlEPTB;MD60NlUhdk1? MYTTRW5ITVJ?
ES1 Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:1U2lEPTB;MD60N{BvVQ>? MY\TRW5ITVJ?
HCE-T NH;VeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjCT5lLUUN3ME2wMlQ{QSCwTR?= M4TGWXNCVkeHUh?=
OS-RC-2 MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjoU2NKSzVyPUCuOFQhdk1? NYq1dpdiW0GQR1XS
MFH-ino M2nYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS0TWM2OD1yLkS0N{BvVQ>? MmO4V2FPT0WU
OCUB-M M4WyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrIZVZ1UUN3ME2wMlQ1PyCwTR?= M{TDVXNCVkeHUh?=
CP66-MEL NHzJU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\PfWlEPTB;MD60O|Mhdk1? MUfTRW5ITVJ?
LB771-HNC NFLZcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PqVGlEPTB;MD60O|Qhdk1? NFH3cHBUSU6JRWK=
DSH1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfLZpJKSzVyPUCuOFghdk1? MoDCV2FPT0WU
HUTU-80 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwNUOzJI5O MVzTRW5ITVJ?
CESS MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPxTWM2OD1yLkWzPEBvVQ>? NWXZe4hIW0GQR1XS
NCI-H747 M3G3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofqTWM2OD1yLkWzPUBvVQ>? MXnTRW5ITVJ?
HT-144 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwNUe2JI5O NYTrWpB1W0GQR1XS
COLO-829 NHLxNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNkG0JI5O MXrTRW5ITVJ?
A4-Fuk M3K1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvITWM2OD1yLk[yN{BvVQ>? NETJTWtUSU6JRWK=
GI-ME-N M3rW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwNkO0JI5O NVi5SHNJW0GQR1XS
LB831-BLC MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPJZ3JKSzVyPUCuOlQyKG6P MYfTRW5ITVJ?
HOP-62 NUfLNnhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmwTWM2OD1yLk[0O{BvVQ>? NULUOZo5W0GQR1XS
BB49-HNC NHPvb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwNkWyJI5O MWLTRW5ITVJ?
D-336MG NH7xU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwNkW3JI5O NXPxfYt7W0GQR1XS
TK10 NF7DemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDhTWM2OD1yLk[3PUBvVQ>? MljGV2FPT0WU
Ramos-2G6-4C10 NVTuVZdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu3UldKSzVyPUCuOlk{KG6P MkTwV2FPT0WU
LB373-MEL-D M1yzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXSTVI6UUN3ME2wMlchdk1? NIHwZ41USU6JRWK=
SF126 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f3OWlEPTB;MD63NFEhdk1? NEPxXpdUSU6JRWK=
UACC-257 NFPYZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTkTWM2OD1yLkexJI5O M3W4N3NCVkeHUh?=
KINGS-1 NXLMS4RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFviU3VKSzVyPUCuO|IzKG6P MkjMV2FPT0WU
LS-513 M1PEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXEbm9KSzVyPUCuO|M6KG6P MVjTRW5ITVJ?
GI-1 NU\CUHlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPiTWM2OD1yLke2OEBvVQ>? M2r0ZXNCVkeHUh?=
ES7 NH\0V2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnYbnBHUUN3ME2wMlc3PiCwTR?= MX7TRW5ITVJ?
LB2241-RCC M3m0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjk[YRKSzVyPUCuPFA1KG6P NFjz[XBUSU6JRWK=
D-263MG NHywOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;iTWM2OD1yLkiwO{BvVQ>? NYHnbJRSW0GQR1XS
SW684 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV24eoJ6UUN3ME2wMlgzOSCwTR?= M2PDR3NCVkeHUh?=
ML-2 NFPkUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwOEKxJI5O NVnKOJZnW0GQR1XS
SK-LMS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLK[217UUN3ME2wMlg2PCCwTR?= NGjHdoVUSU6JRWK=
TE-5 M1jaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3UWZduUUN3ME2wMlg3PSCwTR?= NFPRcllUSU6JRWK=
QIMR-WIL NFvod|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P2TmlEPTB;MD64PFkhdk1? NFrNfldUSU6JRWK=
NCI-H1355 M3zUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP0UJpKSzVyPUCuPFk2KG6P NWjEVmhZW0GQR1XS
SNB75 NYfSUoUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnENlc{UUN3ME2wMlkyOiCwTR?= MULTRW5ITVJ?
RXF393 NV;NSJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwOUG0JI5O M4P0Z3NCVkeHUh?=
IST-MEL1 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGftVnRKSzVyPUCuPVE4KG6P MWnTRW5ITVJ?
SF268 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDWVGxrUUN3ME2wMlkzOyCwTR?= MlvqV2FPT0WU
KALS-1 Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwOUK1JI5O MULTRW5ITVJ?
HC-1 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LLfWlEPTB;MD65O|Uhdk1? NW[zfXJyW0GQR1XS
SW872 NY\wNZBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL2dlVKSzVyPUCuPVk3KG6P M2XlOHNCVkeHUh?=
PSN1 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3viS2lEPTB;MT6wNUBvVQ>? MXHTRW5ITVJ?
TE-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnYboJHUUN3ME2xMlA{KG6P MmL0V2FPT0WU
TE-10 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzvTmhbUUN3ME2xMlA{KG6P NXK4dmZoW0GQR1XS
RKO Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorvTWM2OD1zLkC2JI5O M{fo[XNCVkeHUh?=
LC-2-ad NHHleHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP2RWFKSzVyPUGuNFghdk1? NF;jZmRUSU6JRWK=
SK-MM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3qfFlKSzVyPUGuNFkhdk1? NYHudotnW0GQR1XS
VA-ES-BJ NYPJR4xGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwMEmgcm0> NU\kPXRwW0GQR1XS
MZ7-mel MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwMEmgcm0> M4XNcXNCVkeHUh?=
D-392MG NGrWUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XZbGlEPTB;MT6xJI5O MV7TRW5ITVJ?
CCRF-CEM NE\LeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwMUOgcm0> NHrEdlBUSU6JRWK=
EM-2 NYD2U45{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDjcYpbUUN3ME2xMlE3KG6P MnnQV2FPT0WU
HAL-01 M{PlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjvTWM2OD1zLkG4JI5O M33GO3NCVkeHUh?=
TE-8 NVXofWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjaT5VKSzVyPUGuNVkhdk1? MUfTRW5ITVJ?
NCI-H1882 NX:2U3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjDfFZKSzVyPUGuNkBvVQ>? M1rCOXNCVkeHUh?=
Daudi NVXQPYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwMkKgcm0> NHvhWWpUSU6JRWK=
BL-41 M{PHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwMkWgcm0> NYC2R|VyW0GQR1XS
SR MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\BdJFKSzVyPUGuNlUhdk1? M13ZZXNCVkeHUh?=
KM12 NIHPUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD0TWM2OD1zLkK3JI5O NFrlVoRUSU6JRWK=
K5 NX3qNI5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULZcol5UUN3ME2xMlI5KG6P MVTTRW5ITVJ?
A3-KAW NXSxfJh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHSeWZKSzVyPUGuNlghdk1? NX7pfmFGW0GQR1XS
CMK NXPue|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr3XVdQUUN3ME2xMlI6KG6P NFnsfIdUSU6JRWK=
Calu-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3jTWM2OD1zLkK5JI5O M{C2e3NCVkeHUh?=
IST-SL2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwM{Ggcm0> M2H3R3NCVkeHUh?=
OPM-2 NULoWJJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwM{Ogcm0> NWG2ZXVMW0GQR1XS
DU-4475 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Gc2lEPTB;MT6zOkBvVQ>? NXvScZczW0GQR1XS
ECC12 NXrMOXpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33JemlEPTB;MT6zO{BvVQ>? NF;oWJFUSU6JRWK=
L-540 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHIcXdKSzVyPUGuN|chdk1? MVnTRW5ITVJ?
CAS-1 NE\IOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XXN2lEPTB;MT6zO{BvVQ>? M{fRPXNCVkeHUh?=
PF-382 NI\KeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwNEegcm0> NGHhWm9USU6JRWK=
LS-411N NV7I[45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomyTWM2OD1zLkWzJI5O M2DGWnNCVkeHUh?=
NCI-H69 NXvKUpp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;3eYlKSzVyPUGuOVQhdk1? NGPMbWJUSU6JRWK=
NB12 NHSyepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwNU[gcm0> M3O4UXNCVkeHUh?=
HEL NUTRfZNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEiySZpKSzVyPUGuOlEhdk1? NUfMPGVyW0GQR1XS
GCIY Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PYbGlEPTB;MT62NkBvVQ>? NGTYbmlUSU6JRWK=
EHEB MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M371W2lEPTB;MT62O{BvVQ>? MYfTRW5ITVJ?
TGBC1TKB MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnHRWRKSzVyPUGuO|Ehdk1? M2PtWnNCVkeHUh?=
KURAMOCHI M4\YbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTn[nhvUUN3ME2xMlczKG6P MlTiV2FPT0WU
U-266 NGX1TllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXQTWM2OD1zLke2JI5O M4nsXXNCVkeHUh?=
LC4-1 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDPNFJPUUN3ME2xMlc6KG6P NUL4OXZZW0GQR1XS
NCI-H2126 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDJTWM2OD1zLkigcm0> MV3TRW5ITVJ?
NCI-H1092 NWDnfIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwODDuUS=> NI\MS4xUSU6JRWK=
GB-1 M4f1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwOEGgcm0> MUPTRW5ITVJ?
MV-4-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDFTWM2OD1zLkiyJI5O MXjTRW5ITVJ?
Becker MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzQTWM2OD1zLkizJI5O M1Xlc3NCVkeHUh?=
MPP-89 NF;BXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3a[Zp3UUN3ME2xMlg6KG6P NHnQXnBUSU6JRWK=
BE-13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPLfpRKSzVyPUGuPVMhdk1? NX7MSG9XW0GQR1XS
697 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jSOWlEPTB;MT65PUBvVQ>? MojiV2FPT0WU
NKM-1 M{\2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJibl2= NH7yUYtUSU6JRWK=
NB13 NIjS[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;GSnk{UUN3ME2yJI5O NYPReVUxW0GQR1XS
LS-123 NGn3XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq0TWM2OD1{LkCyJI5O MUXTRW5ITVJ?
NB17 NYDLbpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTBOWJbUUN3ME2yMlA1KG6P Ml;GV2FPT0WU
LAN-6 NYrKTm5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\5b3NWUUN3ME2yMlA2KG6P NGHjV|NUSU6JRWK=
EW-24 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXHXHdZUUN3ME2yMlA5KG6P NX7OWGpzW0GQR1XS
NOS-1 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjiO4VkUUN3ME2yMlEyKG6P MnrHV2FPT0WU
BL-70 NWryT4o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwMUKgcm0> NFLKcVNUSU6JRWK=
GT3TKB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7rbGhiUUN3ME2yMlEzKG6P NEH0eGVUSU6JRWK=
HH M3z4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vvVWlEPTB;Mj6xN{BvVQ>? M2nhdHNCVkeHUh?=
KE-37 M13BTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfBb|NrUUN3ME2yMlE{KG6P MorPV2FPT0WU
MOLT-4 NYjWdIF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\KdIpKSzVyPUKuNVMhdk1? MWDTRW5ITVJ?
EKVX NY\N[VBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwMUSgcm0> NE\WbZBUSU6JRWK=
KGN Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInGWo1KSzVyPUKuNVUhdk1? M1r2O3NCVkeHUh?=
ES4 NF\NOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTUV3ZSUUN3ME2yMlE3KG6P NGewcGNUSU6JRWK=
SJSA-1 NIP6fHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPUemJKSzVyPUKuNlEhdk1? M3nBO3NCVkeHUh?=
KMOE-2 M3mwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HTZ2lEPTB;Mj6yN{BvVQ>? MY\TRW5ITVJ?
NB5 NXO1XZFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37sZmlEPTB;Mj6yO{BvVQ>? NWrUbJlVW0GQR1XS
BC-1 NITTcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXQS|NKSzVyPUKuN|Ehdk1? M2PoV3NCVkeHUh?=
NB10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwM{Kgcm0> NVu5[oxvW0GQR1XS
RPMI-8226 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PFU2lEPTB;Mj6zOUBvVQ>? MmD6V2FPT0WU
SCC-3 M1y2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJwM{egcm0> M2K4OnNCVkeHUh?=
ARH-77 NYXQbmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT0cZBlUUN3ME2yMlM5KG6P M1LzOnNCVkeHUh?=
NCI-H748 M4HScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;0XnVuUUN3ME2yMlM6KG6P MYrTRW5ITVJ?
KU812 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITQcHBKSzVyPUKuOFIhdk1? Mm\TV2FPT0WU
NCI-H64 M1vs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwNESgcm0> MWDTRW5ITVJ?
NB69 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jXeGlEPTB;Mj60OkBvVQ>? NEnkd|RUSU6JRWK=
KNS-81-FD M4ThdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7sVVBKSzVyPUKuOFghdk1? MkT1V2FPT0WU
LB1047-RCC NYTCdIliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvJd3hKSzVyPUKuOVchdk1? Mlr3V2FPT0WU
EB-3 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;PRmlEPTB;Mj62OkBvVQ>? M{jKdnNCVkeHUh?=
Mo-T M3nGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TU[GlEPTB;Mj63OEBvVQ>? NWfDOphVW0GQR1XS
EW-16 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwN{Wgcm0> MUDTRW5ITVJ?
CTV-1 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHkZZVYUUN3ME2yMlghdk1? NXvV[5NCW0GQR1XS
ETK-1 NGfBOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nqNmlEPTB;Mj64OEBvVQ>? NV31eHNlW0GQR1XS
C2BBe1 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJwOEmgcm0> MlXMV2FPT0WU
MOLT-16 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwOEmgcm0> NVG4OYo5W0GQR1XS
SW954 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOzTWM2OD1{Lkmgcm0> MmTKV2FPT0WU
HT MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC0bWRKSzVyPUOuNFIhdk1? M3zHcHNCVkeHUh?=
KARPAS-299 M171Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTGTWM2OD1|LkC2JI5O MYrTRW5ITVJ?
MONO-MAC-6 M1Pn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjzSpZKSzVyPUOuNUBvVQ>? M1LpW3NCVkeHUh?=
CGTH-W-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnQcXhKSzVyPUOuNUBvVQ>? NFPTVXZUSU6JRWK=
SK-PN-DW Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTNwMUSgcm0> MYXTRW5ITVJ?
CW-2 NUH1d5lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfiVVlKSzVyPUOuNlEhdk1? MnzjV2FPT0WU
SK-N-DZ M2LQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFflXpVKSzVyPUOuNlYhdk1? M1Ta[3NCVkeHUh?=
NEC8 NXG0dG1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T2OWlEPTB;Mz6zOUBvVQ>? MXrTRW5ITVJ?
LB996-RCC NHvpdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHZNGlKSzVyPUOuOEBvVQ>? M{j1SXNCVkeHUh?=
DB NEXWd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNwNEGgcm0> MVnTRW5ITVJ?
TE-15 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTNwNEOgcm0> MXXTRW5ITVJ?
COR-L88 M2nLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInkV5lKSzVyPUOuOFchdk1? NUjScmgxW0GQR1XS
LAMA-84 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXsTWM2OD1|LkS5JI5O MYLTRW5ITVJ?
MEG-01 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[yfllKSzVyPUOuOFkhdk1? MoD4V2FPT0WU
LOXIMVI MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLVU49KSzVyPUOuOUBvVQ>? NWnjc5B5W0GQR1XS
RPMI-8402 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPLeWhDUUN3ME2zMlUhdk1? NYjwUIxQW0GQR1XS
KARPAS-45 M2jzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\DbYRXUUN3ME2zMlU1KG6P NGHie4lUSU6JRWK=
HCC1187 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXSTWM2OD1|LkW0JI5O NVjZVJU5W0GQR1XS
MZ1-PC NH[2[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jmdWlEPTB;Mz61OEBvVQ>? NH7SdW1USU6JRWK=
no-11 M2r6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzHTWM2OD1|LkW1JI5O NVPGWnREW0GQR1XS
EVSA-T NGjNSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS3enVKSzVyPUOuOkBvVQ>? NIDiT5BUSU6JRWK=
DJM-1 NGHGVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwNkOgcm0> NWXldJplW0GQR1XS
COLO-684 NH[3OZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH1XlZKSzVyPUOuOlYhdk1? Ml7qV2FPT0WU
NMC-G1 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\NSWp4UUN3ME2zMlY5KG6P MYPTRW5ITVJ?
LC-1F M2jRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvIPIdKSzVyPUOuO|Qhdk1? NEPycoVUSU6JRWK=
RL95-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L6RmlEPTB;Mz63PUBvVQ>? NGCzXHlUSU6JRWK=
COLO-320-HSR MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qc2lEPTB;Mz65NkBvVQ>? Mn7DV2FPT0WU
RCC10RGB NGPMZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3HfXlKSzVyPUOuPVMhdk1? M1TtS3NCVkeHUh?=
HD-MY-Z M4ryNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwOUOgcm0> MXTTRW5ITVJ?
NCI-H2141 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTRwMEWgcm0> MYXTRW5ITVJ?
K-562 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7YXJBKSzVyPUSuNVIhdk1? MnfDV2FPT0WU
NCI-H1648 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LnZWlEPTB;ND6xN{BvVQ>? MVPTRW5ITVJ?
OMC-1 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTRwMUigcm0> NE\vSmFUSU6JRWK=
LB647-SCLC NF3SfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTRwMkKgcm0> NVuzcWtkW0GQR1XS
TE-12 NFf3fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrhTWM2OD12LkK1JI5O NGnuVXZUSU6JRWK=
NOMO-1 NF;oTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK5Voo{UUN3ME20MlM{KG6P NGfodnpUSU6JRWK=
Raji MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[wRm5xUUN3ME20MlQ3KG6P MW\TRW5ITVJ?
NALM-6 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn0NXFkUUN3ME20MlQ6KG6P M4fjVnNCVkeHUh?=
HL-60 M3fpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:zTXN7UUN3ME20MlY4KG6P Mm\YV2FPT0WU
IST-SL1 NIK3NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DQd2lEPTB;ND62PEBvVQ>? NHzse4lUSU6JRWK=
MHH-PREB-1 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HuXGlEPTB;ND64OkBvVQ>? Mny1V2FPT0WU
MHH-NB-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK3d2pqUUN3ME20MlkyKG6P NHnhXYtUSU6JRWK=
JiyoyeP-2003 NY\wfWhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf2epZKSzVyPUWgcm0> NF;4eVhUSU6JRWK=
SBC-1 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LMT2lEPTB;NT6wNUBvVQ>? MonDV2FPT0WU
CHP-126 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrOdZNpUUN3ME21MlA3KG6P NF;Gd2lUSU6JRWK=
LU-139 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3npU2lEPTB;NT6xN{BvVQ>? MnfTV2FPT0WU
NCI-SNU-5 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrNcI0zUUN3ME21MlE4KG6P MlfDV2FPT0WU
SW962 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfpe4xvUUN3ME21MlIyKG6P Mme4V2FPT0WU
EW-1 NV7xR4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTVwM{Ggcm0> MnTLV2FPT0WU
NCI-H1417 NGnl[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnS[pdEUUN3ME21MlUyKG6P M3S5dXNCVkeHUh?=
LU-65 NVXu[3h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmzWlZKSzVyPUWuPFQhdk1? M4PNfnNCVkeHUh?=
D-502MG NGLCboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXMZYJKSzVyPU[uN|chdk1? NIr2VYJUSU6JRWK=
BC-3 NWfkdHVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILRPIpKSzVyPU[uOlEhdk1? MlTXV2FPT0WU
GDM-1 NFT0eVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPxTWM2OD14Lke3JI5O M3nw[3NCVkeHUh?=
NCI-H2196 NHvzTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTZwODDuUS=> NXfVc2RSW0GQR1XS
NB1 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH0XY9KSzVyPU[uPFghdk1? MY\TRW5ITVJ?
NCI-H345 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfVTWM2OD15LkKgcm0> NFvBWoRUSU6JRWK=
SU-DHL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDRTWM2OD15LkK0JI5O MVXTRW5ITVJ?
JVM-2 M3HEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjLVpJ{UUN3ME23MlI5KG6P NYTB[lJ[W0GQR1XS
LU-134-A NHviNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluyTWM2OD15LkO5JI5O NFfjXHFUSU6JRWK=
NCI-H1694 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETC[49KSzVyPUeuOVghdk1? MYPTRW5ITVJ?
NCI-SNU-16 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL2[lhKSzVyPUeuOlUhdk1? NITkOG5USU6JRWK=
L-363 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTdwNzDuUS=> NV3EbnJDW0GQR1XS
KG-1 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LOTWlEPTB;Nz65OEBvVQ>? NWHkbHZtW0GQR1XS
MN-60 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nIXWlEPTB;OD6xOEBvVQ>? NWH2fllDW0GQR1XS
NB6 NYTR[lhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRThwNEigcm0> Mn;MV2FPT0WU
MLMA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjTcYRJUUN3ME24Mlg2KG6P M4PXXnNCVkeHUh?=
ATN-1 MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrWU|ZMUUN3ME24Mlg6KG6P NXzOWnN[W0GQR1XS
SK-NEP-1 NUPXc3gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTlwMEGgcm0> MnqyV2FPT0WU
DMS-114 M1\VOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDGfYREUUN3ME25MlYzKG6P MWPTRW5ITVJ?
CTB-1 M1nicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XqXWlEPTB;OT62O{BvVQ>? M2nhenNCVkeHUh?=
NCI-H2081 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH75OndKSzVyPUGwMlA6KG6P MXrTRW5ITVJ?
ES5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfo[JVbUUN3ME2xNE4{QCCwTR?= NGLmXlRUSU6JRWK=
HCC1599 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KxRmlEPTB;MUGuPVEhdk1? NGXufpBUSU6JRWK=
NCI-H23 MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXiTWM2OD1zMj6xNkBvVQ>? NUmwTmp6W0GQR1XS
NCI-H1581 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF{LkK4JI5O MlXsV2FPT0WU
JVM-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF{Lkm5JI5O MUDTRW5ITVJ?
NCI-SNU-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF|LkG5JI5O M1;4OHNCVkeHUh?=
NB7 NHX3SXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\uSm9KSzVyPUG1MlkzKG6P NFXZVJlUSU6JRWK=
JAR NWTWSY9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\4XZp3UUN3ME2xOk4yOyCwTR?= M3LNZnNCVkeHUh?=
TGW NXfwVlhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rGbWlEPTB;MU[uOFghdk1? NYXidG9CW0GQR1XS
U-87-MG MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF4Lke2JI5O NW\TcGwyW0GQR1XS
NCI-H1436 M375dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF5LkCxJI5O NVPoU4h[W0GQR1XS
GOTO NFnoRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLMeWtEUUN3ME2xO{4xPiCwTR?= MVzTRW5ITVJ?
COLO-800 NHHLWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF5Lk[0JI5O NGHtOIdUSU6JRWK=
MFM-223 NXXPNlNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPWTWM2OD1zNz65NUBvVQ>? NUDqUWRtW0GQR1XS
EW-18 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzvTWM2OD1zNz65OkBvVQ>? M4GxOnNCVkeHUh?=
NB14 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPDTWM2OD1zNz65PEBvVQ>? NV\ZSo5CW0GQR1XS
EB2 M1nWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17Pe2lEPTB;MUiuNFghdk1? MoLzV2FPT0WU
EoL-1- NF\LWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S3emlEPTB;MUiuN|Ehdk1? MVPTRW5ITVJ?
NCCIT M2fDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfXbFhSUUN3ME2xPE4{PiCwTR?= M1rjdHNCVkeHUh?=
DG-75 M3rkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zmUGlEPTB;MUiuOlEhdk1? NXvEcVVbW0GQR1XS
HCC2218 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\QOG5KSzVyPUG5MlUhdk1? MXfTRW5ITVJ?
TE-6 NETBUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qwcGlEPTB;MkCuNFghdk1? MojsV2FPT0WU
SF539 M2fi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfObolKSzVyPUKwMlY4KG6P NIm3bmpUSU6JRWK=
NCI-H446 M1TuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTWdIVKSzVyPUKxMlE5KG6P MXPTRW5ITVJ?
IST-MES1 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDQXZRKSzVyPUKyMlc4KG6P NYLhXYNzW0GQR1XS
NCI-H82 NGroPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{exRmlEPTB;MkOuNFIhdk1? NF\QV3JUSU6JRWK=
HCC2157 NEexO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ|LkGzJI5O MWfTRW5ITVJ?
EW-12 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TSOmlEPTB;MkOuNVchdk1? Ml\BV2FPT0WU
SIMA NHniclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;yd41KSzVyPUKzMlM5KG6P MmnTV2FPT0WU
DOHH-2 M1HJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPMZnl4UUN3ME2yN{41PSCwTR?= NGPSWJlUSU6JRWK=
IM-9 NEmwd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDO[ItiUUN3ME2yN{42PCCwTR?= NYruZmlNW0GQR1XS
EC-GI-10 NXu0VmVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULlPGt{UUN3ME2yOE4zOyCwTR?= MYLTRW5ITVJ?
HDLM-2 NX\MfpBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJ2LkW0JI5O M{Pj[nNCVkeHUh?=
LS-1034 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[3XoRKSzVyPUK1Mlc2KG6P MYLTRW5ITVJ?
REH M4L4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrn[mpEUUN3ME2yOk41OSCwTR?= MW\TRW5ITVJ?
LU-165 MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT2TWM2OD1{Nj63NkBvVQ>? NInHd4JUSU6JRWK=
NH-12 NInNWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPjTWM2OD1{Nz62O{BvVQ>? NETqUWVUSU6JRWK=
WSU-NHL NWHJXnNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\yN2lEPTB;MkiuN|khdk1? NVjvSIRZW0GQR1XS
ECC4 NXe0TVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\FcWlEPTB;MkiuO|khdk1? NEnpdYRUSU6JRWK=
OCI-AML2 M4HwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ7Lk[5JI5O NV;rOVE3W0GQR1XS
EW-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXvTWM2OD1|MD61PUBvVQ>? MVHTRW5ITVJ?
NCI-H526 NYq3fYlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljmTWM2OD1|Mj61OEBvVQ>? MXPTRW5ITVJ?
NCI-H719 NHftXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULvRlhFUUN3ME2zOE4{OSCwTR?= M2S3S3NCVkeHUh?=
KARPAS-422 M3rqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jYd2lEPTB;M{WuNFQhdk1? M4XCbHNCVkeHUh?=
SK-MEL-1 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj4UGJwUUN3ME2zOU4yPyCwTR?= NWPxPFF7W0GQR1XS
ES3 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTN3LkG5JI5O NYjTSmEyW0GQR1XS
UACC-812 NXTqRm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVztdJNEUUN3ME2zOU41PCCwTR?= MUDTRW5ITVJ?
C8166 NIK4SZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f2UmlEPTB;M{WuO{BvVQ>? M4m2XnNCVkeHUh?=
MDA-MB-134-VI NF[3ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN3Lki3JI5O NVGweWVvW0GQR1XS
D-283MED MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLPbZFtUUN3ME2zO{44QSCwTR?= MX7TRW5ITVJ?
SHP-77 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDMUIRoUUN3ME2zPE4xOyCwTR?= NFPBRpFUSU6JRWK=
NCI-H2227 NWi5VW04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLVTWM2OD12MD60PUBvVQ>? NGXPZoJUSU6JRWK=
SKM-1 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLXXFRsUUN3ME20Nk43OyCwTR?= NGC3Z|JUSU6JRWK=
L-428 NITGeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjHTWM2OD12Mz64OkBvVQ>? M3\HN3NCVkeHUh?=
RPMI-6666 M2PS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PBWWlEPTB;NEWuPFkhdk1? NEDVNVZUSU6JRWK=
NCI-H716 NHGwO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PhdGlEPTB;NEiuPFEhdk1? MkLuV2FPT0WU
DMS-79 NFrD[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTVyLkexJI5O M3:wU3NCVkeHUh?=
RS4-11 M{jVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4ZotKSzVyPUWwMlg5KG6P NYLORWp[W0GQR1XS
NCI-H720 NH;TR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVzLkGxJI5O NFzNRmVUSU6JRWK=
MC-CAR NUPLUJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHRVndKSzVyPUWxMlUzKG6P Mmq4V2FPT0WU
TALL-1 NGDTRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTV|LkmxJI5O NFrsUY5USU6JRWK=
NCI-N87 M1P1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTneHdKSzVyPUW0MlE5KG6P MYHTRW5ITVJ?
P30-OHK NH3NVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjHeWtKSzVyPUW0MlYyKG6P M2S0fXNCVkeHUh?=
LP-1 M3zPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZzLkK4JI5O NXP3doo2W0GQR1XS
YT MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\DTWM2OD14MT64JI5O MVzTRW5ITVJ?
MRK-nu-1 NVLBTlJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD0TWM2OD14MT64NkBvVQ>? NUn5e5lLW0GQR1XS
BT-474 NXTLZWFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;LelBZUUN3ME22OUBvVQ>? MkTFV2FPT0WU
NCI-H322M M2TyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrkdWlbUUN3ME22Ok4yOSCwTR?= MofIV2FPT0WU
NCI-H128 M{jnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj1bmdzUUN3ME23OE44PyCwTR?= MlzoV2FPT0WU
KMS-12-PE MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv6cpl{UUN3ME23Ok4zPCCwTR?= M1qxTnNCVkeHUh?=
KP-N-YS M3f3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDQTWM2OD15Nj63OEBvVQ>? NYnXfJpOW0GQR1XS
ALL-PO M{DKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXZTWM2OD15Nz62OkBvVQ>? NEOwRlZUSU6JRWK=
EW-13 NWf2[4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnHSXNKSzVyPUe3Mlc3KG6P NYTYNnlKW0GQR1XS
EW-11 NU\2d297T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF30cGVKSzVyPUe4MlUzKG6P Ml;5V2FPT0WU
SK-N-FI M{fW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7rTWM2OD16MD6yJI5O M1r1XnNCVkeHUh?=
CAL-148 M4fpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\vO|NWUUN3ME24NU45PCCwTR?= NFqzSoNUSU6JRWK=
RL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq0TWM2OD16Nj6wPUBvVQ>? MYLTRW5ITVJ?
AM-38 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHqbWZGUUN3ME24PE4xQCCwTR?= M17WPHNCVkeHUh?=
RH-1 NWnkTHVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrQdolKSzVyPUm5Mlg2KG6P MnLDV2FPT0WU
NCI-H1770 NUm0d4JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LGcGlEPTB;MUCyMlQ6KG6P MlnDV2FPT0WU
SIG-M5 M3;UZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH5eFJ{UUN3ME2xNFUvODZibl2= NWPkSmFMW0GQR1XS
GR-ST M2nES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT6N3V1UUN3ME2xNVMvOzRibl2= NI\INVVUSU6JRWK=
ST486 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG2e2RKSzVyPUGxOE4xPiCwTR?= MVnTRW5ITVJ?
NCI-H1650 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrGOXNEUUN3ME2xNVUvOjlibl2= NXS0VnlCW0GQR1XS
MHH-CALL-2 NHXI[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HDZWlEPTB;MUG1Mlchdk1? NUPGZ|FnW0GQR1XS
BV-173 NXTjd5hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rB[mlEPTB;MUKyMlcyKG6P MkLFV2FPT0WU
MC116 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnraTWM2OD1zNEiuPFUhdk1? MWHTRW5ITVJ?
NCI-H524 M33lZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe0dmdvUUN3ME2xOVkvOSCwTR?= MVrTRW5ITVJ?
SCLC-21H Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF3OT60NUBvVQ>? M33hZXNCVkeHUh?=
NCI-H1304 NIXLSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrCTWM2OD1zNkmuNlEhdk1? MUTTRW5ITVJ?
NCI-H510A NY\MWmlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;v[mlEPTB;MUi1MlM4KG6P NUP2ZXh1W0GQR1XS
NCI-H209 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfoUJdtUUN3ME2xPVYvPTJibl2= NF7wNoZUSU6JRWK=
KM-H2 NGriOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\4TWM2OD1zOUeuNFUhdk1? MnLRV2FPT0WU
NCI-H1395 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj1O5BKSzVyPUKxNE4yOyCwTR?= MXHTRW5ITVJ?
NCI-H1155 NVX1XI81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXqPXpKSzVyPUKzNE4{OiCwTR?= M3;aVXNCVkeHUh?=
COR-L279 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXwcGxKSzVyPUK1Nk4yPyCwTR?= M4nIOXNCVkeHUh?=
NCI-H1299 NWHFU|Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ4MT63NUBvVQ>? MoDVV2FPT0WU
EW-22 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nVc2lEPTB;Mk[zMlc2KG6P Mo\VV2FPT0WU
SK-MEL-2 NWPYcYNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\GdFdKSzVyPUK4NU46KG6P NF60[IdUSU6JRWK=
KASUMI-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi3XpRQUUN3ME2yPFMvODVibl2= NFHzfZJUSU6JRWK=
NCI-H187 NX\hepBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnKenZtUUN3ME2yPFcvODhibl2= MlPtV2FPT0WU
NCI-H2171 M3THcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ6OD65NkBvVQ>? NFH4R4NUSU6JRWK=
LNCaP-Clone-FGC NEfWfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\uTWM2OD1{OUWuNlYhdk1? NX7Ub4RJW0GQR1XS
NCI-H1522 NF;odolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK2XZlKSzVyPUOwO{4xPSCwTR?= NVraVItlW0GQR1XS
SCH NGfhNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN{Mj6yNkBvVQ>? NIXQ[JNUSU6JRWK=
THP-1 M1fuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LM[GlEPTB;M{KyMlYhdk1? MmXMV2FPT0WU
SNU-C1 NVrtNm1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLCN5R5UUN3ME2zOlIvODlibl2= M3LZW3NCVkeHUh?=
CA46 NUfWUWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q4T2lEPTB;M{ezMlY{KG6P MkfHV2FPT0WU
NCI-H1963 M4joWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DMcWlEPTB;M{i2MlE6KG6P M1SzN3NCVkeHUh?=
DEL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWewb3FIUUN3ME2zPVEvOjdibl2= MUfTRW5ITVJ?
TUR NXT5TnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN7Nj62NUBvVQ>? NVfWWFdHW0GQR1XS
NCI-H226 M{T6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGwV2dRUUN3ME20NFMvOjNibl2= NUXkcWxbW0GQR1XS
COLO-668 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\4U2NKSzVyPUSwN{42PyCwTR?= MX;TRW5ITVJ?
CPC-N NVLuUJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPx[HNtUUN3ME20NFMvPzdibl2= M2K3cnNCVkeHUh?=
NCI-H889 MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTR4MT65NkBvVQ>? MorSV2FPT0WU
J-RT3-T3-5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTV|Mj61O{BvVQ>? MnnOV2FPT0WU
MSTO-211H MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrJOWFKSzVyPUW3OE4zPiCwTR?= MlnzV2FPT0WU
SCC-15 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vrSWlEPTB;Nk[3MlQ4KG6P M372cnNCVkeHUh?=
SUP-T1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[yV4ZTUUN3ME22PFYvODRibl2= M373S3NCVkeHUh?=
DMS-153 M4Tocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTd2Nj64N{BvVQ>? NVnveoMyW0GQR1XS
MS-1 M1XhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHTO4J2UUN3ME23OVkvPDJibl2= NGnoR21USU6JRWK=
TC-YIK NH;ubYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTd6MT6wNUBvVQ>? MoTxV2FPT0WU
RPMI-8866 M3fseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFyME[uNlgh|ryP MWjTRW5ITVJ?
KY821 NFSxdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLvTWM2OD1zMEO2MlA1KM7:TR?= MYTTRW5ITVJ?
P31-FUJ M2TFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrUTWM2OD1zMUGyMlc2KM7:TR?= MULTRW5ITVJ?
COLO-824 NX[zdIRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHZTWM2OD1zMk[xMlc5KM7:TR?= MYPTRW5ITVJ?
U-698-M MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D6fWlEPTB;MkK2Nk4yPSEQvF2= NGHtXoNUSU6JRWK=
TE-441-T NHfwc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zrVWlEPTB;MkWyNU44KM7:TR?= NYTxV4lkW0GQR1XS
IMR-5 NIXOW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrvTWM2OD1|NEC5MlYzKM7:TR?= M{\4UHNCVkeHUh?=
NCI-H1838 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrZXo9KSzVyPUSxPFYvOzJizszN MWfTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[4]

+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験:

[5]

+ 展開
  • 細胞株: Human multiple myeloma cells line U266
  • 濃度: ~10 μM
  • 反応時間: 2 days
  • 実験の流れ:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Human plasmacytoma xenografts RPMI 8226
  • 製剤: Saline
  • 投薬量: 1 mg/kg
  • 投与方法: i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4

CAS No. 179324-69-7
保管
in solvent
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID